UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of November 2026
Commission
File Number 001-42468
CELLYAN
BIOTECHNOLOGY CO., LTD
(Exact
name of registrant as specified in its charter)
Cayman
Islands
(Jurisdiction
of incorporation or organization)
4/
Room B1, 5/F., Well Town Industrial Building,
13
Ko Fai Road, Yau Tong, Kowloon
Hong
Kong
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant file or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
On
November 13, 2026, Cellyan Biotechnology Co., Ltd (the “Company”) received a letter from the Listing Qualifications Department
of the Nasdaq Stock Market (“Nasdaq”) stating that because the Company’s Class A ordinary shares had a closing bid
price at or above $1.00 per share for the last 14 consecutive business days, from October 26 through November 12, 2026, the Company had
regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market, as
set forth in Nasdaq Listing Rule 5550(a)(2), and that the matter is now closed.
EXHIBIT INDEX
Exhibits
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized, on November 16, 2026.
| |
CELLYAN
BIOTECHNOLOGY CO., LTD |
| |
|
|
| |
By: |
/s/
Chenyu Liang |
| |
Name: |
Chenyu Liang |
| |
Title: |
Director and Chief Executive
Officer |
Exhibit
99.1
CELLYAN
BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Hong Kong, China, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the “Company”), a
leading provider of over-the-counter (“OTC”) pharmaceutical cross-border
e-commerce supply chain services in Hong Kong, today announced that it received written notification from the Listing Qualifications
Department of The Nasdaq Stock Market LLC (“Nasdaq”) on November 13, 2026, confirming that the Company has regained
compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”)
for continued listing on the Nasdaq Capital Market.
As
previously announced, on January 12, 2026, Nasdaq notified the Company that the closing bid price of the Company’s Class A ordinary
shares had been below US$1.00 per share for 30 consecutive business days and that, as a result, the Company was not in compliance with
the Minimum Bid Price Requirement. Nasdaq provided the Company with an initial compliance period of 180 calendar days, or until July
13, 2026, to regain compliance. To regain compliance, the Company was required to maintain a closing bid price of at least US$1.00 per
share for a minimum of 10 consecutive business days during the compliance period. On July 14, 2026, the Company received written notice
from Nasdaq granting an additional 180 calendar days, or until January 11, 2027, to regain compliance with the Minimum Bid Price Requirement.
Subsequently,
on November 13, 2026, Nasdaq determined that the closing bid price of the Company’s Class A ordinary shares was at least US$1.00
per share for the 14 consecutive business days from October 26 through November 12, 2026. Accordingly, the Company has regained compliance
with the Minimum Bid Price Requirement, and the matter was closed.
About
Cellyan Biotechnology Co., Ltd
Cellyan
Biotechnology Co., Ltd (f.k.a. Hong Kong Pharma Digital Technology Holdings Limited) offers two main categories of services: (i) OTC
pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited
(“Joint Cross Border”), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary,
V-Alliance Technology Supplies Limited.
Through
its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border
provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland
China. Joint Cross Border’s comprehensive service offerings include pre-consultation, product information review, procuring overseas
OTC pharmaceutical products, enlisting products with the Hong Kong Department of Health, obtaining import and export permits, storing
products, packaging, and arranging logistics and end-to-end delivery services for customers.
For
investor and media inquiries please contact:
Cellyan
Biotechnology Co., Ltd
Media
Contact: andy@cell-yan.com
Investor
Relations: stella@cell-yan.com